Everything about dexmeditomidine

Reading File

Finding Sources

Searching PubMed

dexmedetomidine[MeSH Terms]

Finding Sources

Reading File

Searching the Web

dexmedetomidine 2024 2025 new indications clinical uses ICU analgesia

Reading File

I now have comprehensive data from multiple authoritative textbooks. Let me compile the full, detailed answer:

Dexmedetomidine - Complete Reference

1. Drug Identity & Classification

Dexmedetomidine (brand name Precedex) is a highly selective alpha-2 (α2) adrenergic agonist used for sedation, anxiolysis, and analgesia. It is the active S-enantiomer of medetomidine - a veterinary α2-agonist imidazole derivative. Its α2:α1 selectivity ratio is approximately 1620:1, making it far more selective than clonidine (which has a ratio of about 220:1). It is water-soluble and available only as a parenteral formulation.

Katzung's Basic and Clinical Pharmacology, 16th Ed.
Morgan and Mikhail's Clinical Anesthesiology, 7e

2. Mechanism of Action

Dexmedetomidine binds to α2-adrenoceptors in the CNS and periphery. There are three α2-receptor subtypes:

Subtype	Location	Effect
α2A	Locus coeruleus, spinal cord	Sedation, analgesia, sympatholysis
α2B	Peripheral vasculature	Vasoconstriction (transient hypertension with bolus)
α2C	Brain	Modulation of cognition and mood

Sedation: Stimulation of α2A receptors in the locus coeruleus (the brain's primary noradrenergic nucleus) suppresses aminergic arousal and inhibits thalamocortical depolarization - mimicking the endogenous pathway of natural non-REM sleep.

Analgesia: Originates at the spinal cord level via α2A receptor activation, inhibiting nociceptive signal transmission.

Sympatholysis: Suppresses norepinephrine release from sympathetic nerve terminals, causing bradycardia and hypotension.

The EEG signature of dexmedetomidine shows an alpha-delta pattern with fragmented, intermittent sleep spindles (~12 Hz) - quite distinct from the near-continuous alpha oscillations of propofol or sevoflurane, and closely resembling natural sleep spindles.

Miller's Anesthesia, 10e
Katzung's Basic and Clinical Pharmacology, 16th Ed.

3. Pharmacokinetics

Parameter	Detail
Administration	IV only (approved); intranasal and oral used off-label in children
Distribution	Rapid redistribution (minutes); highly lipophilic
Protein binding	~94%, primarily to albumin and α1-acid glycoprotein
Volume of distribution	~118 L
Metabolism	Hepatic - N-methylation, hydroxylation, then glucuronide/sulfate conjugation; CYP450 system involved
Active metabolites	None significant
Elimination half-life	Less than 3 hours (approximately 2 hours)
Context-sensitive half-time	Increases substantially with infusion duration: ~4 min after 10-minute infusion → ~250 min after an 8-hour infusion
Excretion	~95% in urine, ~4% in feces (as metabolites)

Special Populations:

Renal impairment: Reduced protein binding → larger free fraction → longer-lasting sedative effect. Dose should be used cautiously.
Hepatic impairment: Reduced clearance; use with caution in severe liver disease.
Neonates: Significantly reduced clearance.
Elderly: Increased sensitivity; lower doses recommended.
Katzung's Basic and Clinical Pharmacology, 16th Ed.
Morgan and Mikhail's Clinical Anesthesiology, 7e
Barash, Cullen, and Stoelting's Clinical Anesthesia, 9e

4. Pharmacodynamics by Organ System

4a. Central Nervous System

Produces sedation that closely mimics natural sleep - patients are easily arousable (cooperative sedation)
Significantly less respiratory depression than other sedatives/opioids
Provides anxiolysis and mild analgesia
Less amnesia than benzodiazepines
Cerebral effects: Dose-dependent decrease in cerebral blood flow (CBF) and cerebral metabolic rate for oxygen (CMRO2) without significant increase in intracranial pressure (ICP) in most studies. This raises interest in its neuroprotective potential.
Has potential for tolerance and physical dependence with prolonged use

4b. Cardiovascular System

Bolus dose: Transient hypertension (peripheral α2B-mediated vasoconstriction) followed by hypotension
Infusion: Moderate, dose-dependent decreases in heart rate, systemic vascular resistance, and blood pressure
Bradycardia is common; can progress to heart block, severe bradycardia, sinus pause, or asystole - especially when combined with other sympatholytic or cholinergic agents (very high-risk combination)
Responds normally to anticholinergics

4c. Respiratory System

Minimal respiratory depression - this is its hallmark advantage
Small decrease in tidal volume; little change in respiratory rate
Ventilatory response to CO2 is essentially unchanged
Upper airway obstruction from sedation is possible
Synergistic sedative effect when combined with other sedative-hypnotics

4d. Endocrine

Inhibits insulin secretion (via α2 receptors on pancreatic beta cells)
Reduces sympathoadrenal activity perioperatively
Goldman-Cecil Medicine, 2-Vol Set
Katzung's Basic and Clinical Pharmacology, 16th Ed.
Miller's Anesthesia, 10e

5. Clinical Uses & Dosing

5a. ICU Sedation (Primary FDA-Approved Indication)

Approved for short-term (<24 hours) IV sedation of intubated adults
Loading dose: 1 mcg/kg IV over 10 minutes
Maintenance infusion: 0.2 to 0.7 mcg/kg/h (range up to 1.4 mcg/kg/h)
Advantages over benzodiazepines in ICU: More cooperative patients, shorter time on ventilator, shorter ICU stay, decreased incidence of delirium

5b. Procedural Sedation / Awake Procedures

Awake fiberoptic intubation
Awake craniotomy
During regional anesthesia as a supplement
Reduces need for intraoperative opioids and inhalational anesthetics (by 25-40% for inhaled agents)

5c. Pediatric Uses (off-label)

Intranasal premedication: 1-2 mcg/kg; bioavailability ~80%; onset 25-30 min, duration ~85 min. Superior to midazolam in several studies.
Oral premedication: 2.5-4 mcg/kg (less common)
ICU sedation: Loading dose 1-2 mcg/kg over 10 minutes, then 0.5-1 mcg/kg/h
Medical imaging (MRI, CT) - sole sedative for non-invasive procedures
Prevention of emergence delirium after inhalation anesthetics
Children may be more easily aroused from dexmedetomidine than from other agents

5d. Other Uses

Reducing emergence agitation/delirium (especially in children post-inhalation anesthesia)
Regional anesthesia adjunct (perineural use has been investigated to prolong blocks)
Alcohol withdrawal management
Cocaine intoxication (sympatholysis)
Palliative care: Emerging role for delirium control and pain (Systematic Review, 2024 - PMID 38770684)
Morgan and Mikhail's Clinical Anesthesiology, 7e
Miller's Anesthesia, 10e (pediatric section)
Goldman-Cecil Medicine

6. Comparison with Other Sedatives

Feature	Dexmedetomidine	Propofol	Benzodiazepines	Opioids
Arousability	++++ (easily aroused)	++	+	++
Respiratory depression	Minimal	Significant	Moderate	Significant
Analgesia	Yes (mild)	No	No	Yes
Amnesia	Mild	Moderate	Significant	Minimal
Onset of sedation	Slower	Faster	Moderate	Variable
Delirium risk	Lower	Moderate	Higher	Higher
Cardiovascular effect	Bradycardia/hypotension	Hypotension	Minimal	Variable
Natural sleep-like EEG	Yes (closest)	No	Partial	No

7. Adverse Effects & Contraindications

Common Adverse Effects

Bradycardia (most common) - may require treatment with atropine or glycopyrrolate
Hypotension - common with infusion
Transient hypertension - with bolus dosing

Serious / Rare

Severe bradycardia, heart block, sinus pause, cardiac arrest
Sinus arrest - particularly when combined with sympatholytic or vagotonic drugs
Upper airway obstruction (from over-sedation)

Contraindications / Cautions

Severe hepatic impairment (reduce dose)
Pre-existing heart block or severe bradycardia
Advanced heart block without pacemaker
Use with sympatholytic/cholinergic agents - very high risk of extreme bradycardia/arrest
Prolonged use (>24 hours): tolerance, dependence, and potential withdrawal

Drug Interactions

Other CNS depressants: synergistic sedation
Sympatholytic drugs + cholinergic drugs: extreme bradycardia / sinus arrest risk
Effects can be antagonized by α2-antagonists (e.g., atipamezole in veterinary use, yohimbine)
Goldman-Cecil Medicine
Katzung's Basic and Clinical Pharmacology, 16th Ed.
Miller's Anesthesia, 10e; Barash's Clinical Anesthesia, 9e

8. Neuroprotection

Animal studies have demonstrated neuroprotection from hypoxia-ischemia and decreased apoptosis. Human studies in healthy volunteers showed parallel decreases in CMRO2 and CBF. This has generated interest in its use in:

Traumatic brain injury
Post-cardiac surgery neuroprotection
Patients at risk for intracranial hypertension (brain tumor, obstructive hydrocephalus)

However, pediatric TBI case reports have observed bradycardia (especially with therapeutic hypothermia) and some hemodynamic concerns. ICP does not appear to increase. Further studies are needed. Authors of major textbooks do not recommend it as an induction agent for these cases but acknowledge its potential for ongoing sedation needs.

Barash, Cullen, and Stoelting's Clinical Anesthesia, 9e

9. EEG Signature

The spectrogram of dexmedetomidine sedation shows transient, intermittent sleep spindles in the ~12 Hz alpha-wave band. These are very similar morphologically to natural sleep spindles. This contrasts with propofol and sevoflurane, which produce longer, near-continuous alpha oscillations. The unique subcortical (rather than cortical) mechanism explains why patients are far more easily awakened from dexmedetomidine sedation than from equivalent levels of propofol sedation.

Miller's Anesthesia, 10e (Chapter 36)

10. Recent Evidence (2023-2026)

Recent high-quality systematic reviews and meta-analyses confirm and expand dexmedetomidine's role:

PMID	Study	Key Finding
38770684	SR in palliative care (J Palliat Med 2024)	Effective against delirium and pain in palliative care settings
38695625	Cochrane SR, neonates on MV (2024)	Provides sedation/analgesia in ventilated neonates; safety profile still under evaluation
37845426	SR - neonatal analgesia/sedation (J Perinatol 2024)	Appears efficacious and safe in neonates, though evidence is limited
39644147	SR - pediatric pharmacology (Clin Transl Sci 2024)	Significant PK variability in children; weight-based dosing important
37769542	Meta-analysis, NIV sedation (Heart Lung 2024)	Dexmedetomidine is a preferred agent for sedation during non-invasive ventilation

A 2025 narrative review (PMC12652068) summarized 20 years of ICU experience, confirming that dexmedetomidine's "arousable sedation" reduces duration of mechanical ventilation, ICU length of stay, costs, and improves sleep quality - with an important role in preventing and treating ICU delirium and post-ICU syndrome, especially in the elderly.

Summary Card

Feature	Value
Class	α2-adrenergic agonist (highly selective)
Selectivity	α2:α1 = 1620:1
Mechanism	α2A (locus coeruleus) → sedation; spinal α2A → analgesia; sympatholysis
Key advantage	Arousable sedation with minimal respiratory depression
Approved use	Short-term ICU sedation of intubated adults (IV only)
Loading dose	1 mcg/kg IV over 10-15 min
Maintenance	0.2-0.7 mcg/kg/h (up to 1.4)
Half-life	~2 hours (but context-sensitive T½ rises markedly with prolonged infusion)
Main ADR	Bradycardia, hypotension, transient hypertension
Dangerous interaction	Sympatholytic/cholinergic drugs → cardiac arrest risk
Antidote	α2-antagonists (e.g., atipamezole); atropine for bradycardia
Brand name	Precedex

Everything about Tranexamic acid

Reading File

Finding Sources

Searching PubMed

"tranexamic acid"[MeSH Terms]

Searching the Web

tranexamic acid 2024 2025 new indications guidelines clinical use

Reading File

Excellent - I now have comprehensive, multi-source textbook data. Let me compile the full reference answer.

Tranexamic Acid (TXA) - Complete Reference

1. Drug Identity & Classification

Tranexamic acid (brand names: Cyklokapron, Lysteda) is a synthetic antifibrinolytic agent - a lysine analogue that inhibits fibrinolysis by blocking plasminogen/plasmin binding to fibrin. It is 10 times more potent than its analogue epsilon-aminocaproic acid (ε-ACA). It is on the WHO List of Essential Medicines as a drug affecting coagulation.

Tintinalli's Emergency Medicine | Roberts and Hedges' Clinical Procedures in Emergency Medicine | Lippincott Illustrated Reviews: Pharmacology

2. Mechanism of Action

TXA is a competitive analogue of lysine. It works through two mechanisms depending on dose:

Low/therapeutic doses: Competitively occupies the lysine binding sites on plasminogen, preventing plasminogen from binding to fibrin. This blocks plasminogen activation and conversion to plasmin (the main fibrinolytic enzyme).
High doses: Acts as a non-competitive inhibitor of plasmin itself.

The net result is stabilization of the fibrin clot - it is not broken down, hemorrhage is controlled, and blood loss is reduced.

UV-radiation / melasma mechanism: UV radiation induces plasminogen activator production by keratinocytes, leading to melanogenesis via plasmin, arachidonic acid, and fibroblast growth factor, plus neovascularization via VEGF. TXA blocks this pathway by inhibiting plasminogen activation - hence its utility in melasma.

Goodman & Gilman's Pharmacological Basis of Therapeutics | Lippincott Illustrated Reviews: Pharmacology | Current Surgical Therapy 14e

3. Pharmacokinetics

Parameter	Detail
Routes	IV, oral, topical, intranasal (nebulized), intramuscular, intradermal
Bioavailability (oral)	~30-50%
Protein binding	Minimal (~3%)
Volume of distribution	~9-12 L
Metabolism	Minimal hepatic metabolism
Elimination	Primarily renal excretion unchanged (~95% in urine)
Elimination half-life	~2-3 hours (prolonged significantly in renal failure)
Plasma levels	Therapeutic antifibrinolytic concentration maintained for ~7-8 hours after IV dose

Special Populations:

Renal impairment (CKD): Kidney excretion is the main clearance route. TXA has an unpredictable pharmacokinetic profile in advanced CKD. Patients are at particular risk for neurologic side effects (seizures). Reserve for life-threatening bleeding when other treatments fail.
Pregnancy: Can cross the placenta and enters breastmilk. For postpartum hemorrhage, it is recommended to wait until the cord is clamped before administration.
Comprehensive Clinical Nephrology, 7th Ed. | Miller's Anesthesia, 10e

4. FDA-Approved Indications

Indication	Formulation
Heavy menstrual bleeding (menorrhagia)	Oral (Lysteda)
Short-term prevention of bleeding in hemophilia patients undergoing dental extraction	IV/Oral (Cyklokapron)

All other uses described below are off-label (though widely supported by evidence and guidelines).

5. Clinical Uses - Off-Label (Evidence-Based)

5a. Trauma / Hemorrhagic Shock (CRASH-2 Trial)

The landmark CRASH-2 trial (>20,000 patients, multicenter, randomized) established TXA's role in trauma:

Significantly reduced all-cause mortality (14.5% vs. 16%; RR 0.91 [95% CI 0.85-0.97])
Reduced death due to bleeding (4.9% vs. 5.7%; RR 0.85 [95% CI 0.76-0.96])
No increase in vascular occlusive events (MI, stroke, PE)
Time-dependent effect (critical):
- Within 1 hour: RR of death from bleeding reduced by 32%
- 1-3 hours: reduced by 21%
- After 3 hours: potentially harmful - increased risk of death from bleeding (RR 1.44 [95% CI 1.12-1.84])

Dose in trauma: 1 g IV over 10 minutes (loading), then 1 g IV over 8 hours (maintenance)

Key guidance (Bailey & Love, Tintinalli): Give to all trauma patients suspected of significant hemorrhage (SBP <110 mmHg or pulse >110/min), ideally within the first hour from injury, and not after 3 hours.

MATTERs Study: Among 896 consecutive trauma admissions (293 received TXA), although TXA patients were more severely injured, they had lower mortality. Benefit was greatest in those receiving >10 units of PRBCs in 24 hours.

Caveat: A study of 180 trauma patients found fibrinolytic shutdown in 64% (not hyperfibrinolysis). Careful patient selection is advised - not all trauma patients benefit from antifibrinolysis.

Barash, Cullen, and Stoelting's Clinical Anesthesia, 9e | Current Surgical Therapy 14e | Bailey and Love's Surgery, 28e | Tintinalli's Emergency Medicine

5b. Traumatic Brain Injury (CRASH-3 Trial)

CRASH-3 trial (>12,000 patients with TBI, no major extracranial bleeding):

Early TXA (within 3 hours) reduced TBI-related death in mild-to-moderate TBI (GCS 9-15; RR 0.78, CI 0.64-0.95)
Patients with reactive pupils had decreased risk of TBI-related death (RR 0.87)
No benefit in severe TBI
No difference in vascular occlusive events or seizures between groups
Out-of-hospital TXA for moderate-to-severe TBI showed no clear benefit on 6-month functional neurologic outcomes

Dose in TBI: 1 g IV over 10-15 minutes, then 1 g every 8 hours for first 24 hours

Mulholland and Greenfield's Surgery, 7e | Current Surgical Therapy 14e

5c. Postpartum Hemorrhage (WOMAN Trial)

The WOMAN trial (20,060 women randomized):

Reduction in death due to bleeding if TXA given within 3 hours (RR 0.69; 95% CI 0.52-0.91; P = 0.008)
No difference in thromboembolic events or other side effects
ACOG recommends TXA when initial medical therapy for PPH fails
Evidence is inconclusive for prophylactic use to prevent PPH (a 4,079-patient RCT found no benefit when added to oxytocin after vaginal delivery)
Note: Cross the placenta and enters breastmilk - administer after cord clamping

WHO recommendation: Early TXA (within 3 hours of birth) for all clinically diagnosed PPH, regardless of cause.

Cochrane SR 2024 (PMID 39535297): TXA reduces postpartum hemorrhage after Caesarean section.

Lancet IPD meta-analysis 2024 (PMID 39461793): Individual patient data meta-analysis confirming benefit for postpartum bleeding.

Miller's Anesthesia, 10e | Tintinalli's Emergency Medicine

5d. Surgical Blood Loss

TXA is widely used perioperatively to reduce intraoperative and postoperative blood loss:

Surgical Context	Evidence Level
Cardiac surgery	Strong - reduces transfusion requirements
Orthopedic surgery (joint arthroplasty, spine)	Strong - standard of care in many centers
Arthroscopy	Emerging
Spinal surgery	Established
Foot and ankle surgery	Reduces intraoperative blood loss; no difference in complications (2022 meta-analysis)
General surgery	JAMA Surgery meta-analysis 2026 (PMID 41405985): confirmed efficacy in perioperative general surgery

Dose in surgery: 0.5-1 g IV before incision ± maintenance infusion; topical application also used (e.g., directly into surgical field).

Campbell's Operative Orthopaedics, 15e (2026) | Fischer's Mastery of Surgery, 8e

5e. Menorrhagia / Heavy Menstrual Bleeding

Oral: 1.3 g (Lysteda) three times daily for 3-5 days during menstrual bleed
Pooled analysis of two RCTs: significant reduction in mean menstrual blood loss vs. placebo across three treatment cycles
As effective as the levonorgestrel intrauterine coil in a 10-year study (same proportion avoided surgery)
Common adverse events: headache (55%), nausea (15%)
The only FDA-approved oral indication
Berek & Novak's Gynecology

5f. Epistaxis

Topical application: injectable TXA (500 mg in 5 mL) on cotton pledget/nasal packing
RCT: bleeding stopped in 71% of TXA group within 10 minutes vs. 31% of anterior nasal packing group
Reduced rebleeding rates; more patients discharged within 2 hours
Cochrane review of topical TXA: no adverse VTE/MI/stroke events; decreased need for blood transfusion by 45%
Effective for recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT)
Rosen's EM: Moderate-quality evidence supports topical TXA for reducing bleeding at 10 min and re-bleeding at 7 days
Roberts and Hedges' Clinical Procedures in Emergency Medicine | Rosen's Emergency Medicine

5g. Gastrointestinal Bleeding

Meta-analysis 2025 (PMID 40029534): TXA evaluated as treatment for acute GI bleeding - comprehensive SR and meta-analysis confirming potential benefit
Prior large trial (HALT-IT, 2020) found TXA did not reduce death in acute upper GI bleeding but increased seizures - this remains controversial

5h. Melasma / Skin Hyperpigmentation

Topical: 2-5% formulation, applied twice daily
Intradermal: 4 mg/mL; injection frequency ranges from once weekly to once monthly; side effect: injection site burning
Oral: 250-325 mg twice daily; side effects: abdominal bloating, headache
Mechanism: Inhibits UV-induced melanogenesis and neovascularization via plasminogen activation blockade
Meta-analysis 2024 (PMID 38843906): Confirmed TXA as a therapeutic option for melasma management
Screen for thromboembolic risk factors before systemic use; low VTE risk in women (2025 PMC review)
Goodman & Gilman's Pharmacological Basis of Therapeutics

5i. Hemoptysis (Nebulized)

Systematic Review 2025 (PMID 39841268): Nebulized TXA shows promising results in managing hemoptysis as an integrative approach

5j. Other Uses

Dental extractions in hemophiliacs: Mouthwash (5% oral rinse) before and after procedure
Hyphema (traumatic bleeding into anterior chamber of eye): Oral TXA to reduce re-bleeding
Hereditary hemorrhagic telangiectasia (HHT): Oral TXA for recurrent epistaxis
Oral cavity bleeds: Mouthwash preparation

6. Dosing Summary

Indication	Route	Dose
Trauma	IV	1 g over 10 min, then 1 g over 8 h
TBI (within 3 h)	IV	1 g over 10-15 min, then 1 g q8h × 24h
PPH	IV	1 g over 10 min (within 3 h of birth)
Heavy menstrual bleeding	Oral	1.3 g TID × 3-5 days during menses
Surgery	IV	0.5-1 g loading ± maintenance infusion
Dental extraction (hemophilia)	Oral/mouthwash	25 mg/kg TID; 5% mouthwash
Epistaxis	Topical	500 mg in 5 mL on cotton pledget
Melasma	Oral	250-325 mg BID
Melasma	Topical	2-5% cream BID
Melasma	Intradermal	4 mg/mL weekly-monthly

7. Adverse Effects

Adverse Effect	Notes
Thromboembolic events (DVT, PE, MI, stroke)	Primary theoretical concern; not significantly elevated in major trials when given correctly
Seizures	Dose-dependent; especially with high doses (>2 g), rapid IV infusion, or in renal failure. Linked to GABA-A receptor inhibition at high concentrations
Nausea / vomiting	Dose-related; slow IV infusion reduces risk
Hypotension	With rapid IV injection
Visual disturbances	With prolonged use; ophthalmologic monitoring recommended for long-term therapy
Headache / abdominal bloating	With oral use (especially for melasma)
Injection site erythema	With IM administration
Intravascular thrombosis	Key risk - clots formed during treatment are not degraded

Critical note on seizures: TXA inhibits glycine and GABA-A receptors at high concentrations, reducing seizure threshold. Risk is highest in cardiac surgery with high doses, intrathecal/epidural exposure (avoid), and in CKD patients.

8. Contraindications

Contraindication	Type
Active thromboembolic disease (DVT, PE, MI, stroke)	Absolute
Seizure history	Absolute (or use with extreme caution)
Severe renal disease (unpredictable PK, seizure risk)	Relative/Absolute
Coagulopathy (active DIC with pro-coagulant phase)	Relative
Subarachnoid hemorrhage (risk of cerebral ischemia from clot persistence)	Relative
Pregnancy (unless for PPH after cord clamping)	Relative
Hematuria from upper urinary tract (clot in ureter/renal pelvis can obstruct)	Avoid in upper urinary tract bleeding

Campbell's Operative Orthopaedics, 15e | Comprehensive Clinical Nephrology, 7th Ed.

9. Drug Interactions / Combinations

Hormonal contraceptives: Potentially additive thrombotic risk (theoretical, limited evidence)
Factor IX complex / anti-inhibitor coagulant concentrates: Risk of thrombosis
Fibrinolytic agents (streptokinase, tPA): Mutually antagonistic - TXA reverses thrombolysis
Tretinoin / other skin lightening agents: Additive benefit in melasma (combination studied)

10. Comparison: TXA vs. ε-Aminocaproic Acid (EACA)

Feature	Tranexamic Acid	ε-ACA
Potency	10× more potent	1× (reference)
Half-life	Longer	Shorter
Route	IV, oral, topical	IV, oral
FDA approval	Menorrhagia, hemophilia dental extraction	Fibrinolysis states
Evidence in trauma	Extensive (CRASH-2)	Limited

11. Recent Evidence Highlights (2024-2026)

PMID	Study	Key Finding
39461793	Lancet IPD meta-analysis (2024)	TXA reduces death from PPH; early administration critical
39535297	Cochrane SR - PPH post-CS (2024)	TXA reduces hemorrhage after C-section
38843906	SR + meta-analysis - melasma (2024)	TXA is an effective option for melasma
39841268	SR - nebulized TXA in hemoptysis (2025)	Promising role in hemoptysis management
40029534	SR + MA - GI bleeding (2025)	TXA shows benefit in acute GI bleeding
41405985	JAMA Surgery - perioperative general surgery (2026)	Reduces blood loss and transfusion in general surgery

12. Summary Card

Feature	Value
Class	Synthetic antifibrinolytic - lysine analogue
Mechanism	Blocks plasminogen/plasmin lysine binding sites → inhibits fibrinolysis
Potency	10× more than ε-aminocaproic acid
Key trials	CRASH-2 (trauma), CRASH-3 (TBI), WOMAN (PPH), HALT-IT (GI)
Critical time window	Must be given within 3 hours of injury/hemorrhage onset
Standard trauma dose	1 g IV over 10 min → 1 g IV over 8 hours
FDA indications	Heavy menstrual bleeding; hemophilia dental extraction
Most dangerous ADR	Seizures (especially with high doses or renal failure); thromboembolism
Key contraindication	Seizure history, severe renal disease, active thromboembolism, upper urinary tract hematuria
Brand names	Cyklokapron (IV/oral), Lysteda (oral tablet)
WHO status	Essential Medicine

This is a shared conversation. Sign in to Orris to start your own chat.